Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients.

doi:10.1111/j.1365-2141.2006.06390.x

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients.

British journal of haematology - 1 Jan 2007

Malagola Michele, Damiani Daniela, Martinelli Giovanni, Michelutti Angela, Cesana Bruno, Vivo Antonio De, Piccaluga Pier Paolo, Ottaviani Emanuela, Candoni Anna, Geromin Antonella, Tiribelli Mario, Fanin Renato, Testoni Nicoletta, Lauria Francesco, Bocchia Monica, Gobbi Marco, Pierri Ivana, Zaccaria Alfonso, Zuffa Eliana, Mazza Patrizio, Priccolo Giancarla, Gugliotta Luigi, Bonini Alessandro, Visani Giuseppe, Skert Cristina, Bergonzi Cesare, Roccaro Aldo Maria, Filí Carla, Baccarani Michele, Russo Domenico

Abstract excerpt

One hundred and six patients aged </=60 years with newly diagnosed acute myeloid leukaemia (AML) treated with fludarabine-based regimens (cases) were matched with 106 AML patients treated with conventional non-fludarabine-based regimens (controls). The cases and controls were matched by expression of the multidrug resistance P-glycoprotein (MDR-Pgp), measured by flow cytometry as mean fluorescence index (MFI),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Drug Resistance, Multiple

Share to Karyotyping

Share to Leukemia, Myeloid

Share to Remission Induction

Share to Statistics, Nonparametric

Share to Vidarabine

Source

Open in PubMed

Identifiers

PMID: 17222198
DOI: 10.1111/j.1365-2141.2006.06390.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients.PMID 17222198Read ↗

Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia.Semantic proximity Read ↗

Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype.Semantic proximity Read ↗

Phenotypic changes of leukemic cells in a patient with prolympho-plasmacytic leukaemia after treatment with fludarabine.Semantic proximity Read ↗

Expression of multidrug resistance P-glycoprotein in myeloid progenitor cells of different phenotype: comparison between normal bone marrow cells and leukaemia cells.Semantic proximity Read ↗

P-glycoprotein expression in adult acute myeloid leukemia: correlation with induction treatment outcome.Semantic proximity Read ↗

The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives.Semantic proximity Read ↗

Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS.Semantic proximity Read ↗

Multicentric evaluation of the MDR phenotype in leukemia. French Network of the Drug Resistance Intergroup, and Drug Resistance Network of Assistance Publique-Hôpitaux de Paris.Semantic proximity Read ↗

Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.